At AstraZeneca, our aim is to help improve the outcomes of cancer patients with the ambition to one day eliminate cancer as a cause of death. Throughout our history, our innovative science has led to practice-changing medicines for patients with cancer, and although we have come so far, there is still much to be done. We are committed to fostering our research to redefine the breast cancer treatment paradigm.
Immuno Oncology - LCM, is a focus for AstraZeneca. As our understanding of the features that fuel these complex tumor types grow, the way we classify LCM and how to treat it will undoubtedly change, something we are spearheading at AstraZeneca. We are leading an exciting phase of scientific discovery and innovation and are identifying ways of improving outcomes for patient populations that are associated with poor clinical outcomes.
The US Director of Medical Alignment IO LCM based in our Gaithersburg, MD office is a strategic member of the Medical Affairs - Core Medical Team. You are accountable for the design and execution of the Medical Plan, and the alignment of US Medical Affairs scientific activities in support of the brand objectives.
Major Accountabilities:
Powered by
*By registering with our site, you agree to our
Terms and Privacy Policy.